Aurobindo's Eugia Pharma Specialities receives FDA OK for generic Votrient
Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.
Aurobindo’s wholly owned subsidiary company, Eugia Pharma Specialities has received approval from the Food and Drug Administration to manufacture and market pazopanib tablets, 200 mg, which is the generic of Novartis’ Votrient Tablets
The company said it expects generic Votrient will be launched in Q4 FY25.
The approved product has an estimated market of $106 million for the 12 months ending October 2024, per IQVIA.
[Read more: Aurobindo Pharma’s Eugia Pharma Specialities gets FDA OK for generic Pulmicort Respules]
Pazopanib tablets, 200 mg are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.